Steven A Greenberg1. 1. Division of Neuromuscular Disease, Department of Neurology, Brigham and Women's Hospital, and Children's Hospital Informatics Program Harvard Medical School, Boston, Massachusetts 02115, USA. sagreenberg@partners.org
Abstract
PURPOSE OF REVIEW: Inclusion body myositis (IBM) is a poorly understood progressive muscle disease of middle and later life. Its dual pathologies of autoimmunity and unexplained myofiber degeneration and loss have been enigmatic since its earliest descriptions over 40 years ago. No reliable effective therapy currently exists for IBM. This review provides an update of current issues in the pathogenesis and therapy of IBM. RECENT FINDINGS: Recent studies have further defined the clinical features of IBM, including natural history, pattern of muscle involvement, and role of MRI imaging. Further potential immune mediators have been identified. An autoantibody directed against a muscle antigen appears to have high specificity for IBM among muscle diseases. Further evidence for myonuclear degeneration has been reported. SUMMARY: IBM remains a poorly understood muscle disease, although understanding of the pathophysiological mechanisms continues to expand and is supporting new therapeutic approaches.
PURPOSE OF REVIEW: Inclusion body myositis (IBM) is a poorly understood progressive muscle disease of middle and later life. Its dual pathologies of autoimmunity and unexplained myofiber degeneration and loss have been enigmatic since its earliest descriptions over 40 years ago. No reliable effective therapy currently exists for IBM. This review provides an update of current issues in the pathogenesis and therapy of IBM. RECENT FINDINGS: Recent studies have further defined the clinical features of IBM, including natural history, pattern of muscle involvement, and role of MRI imaging. Further potential immune mediators have been identified. An autoantibody directed against a muscle antigen appears to have high specificity for IBM among muscle diseases. Further evidence for myonuclear degeneration has been reported. SUMMARY: IBM remains a poorly understood muscle disease, although understanding of the pathophysiological mechanisms continues to expand and is supporting new therapeutic approaches.
Authors: N A Goyal; T M Cash; U Alam; S Enam; P Tierney; N Araujo; F H Mozaffar; A Pestronk; T Mozaffar Journal: J Neurol Neurosurg Psychiatry Date: 2015-04-09 Impact factor: 10.154
Authors: Thomas E Lloyd; Lisa Christopher-Stine; Iago Pinal-Fernandez; Eleni Tiniakou; Michelle Petri; Alan Baer; Sonye K Danoff; Katherine Pak; Livia A Casciola-Rosen; Andrew L Mammen Journal: Arthritis Care Res (Hoboken) Date: 2016-01 Impact factor: 4.794
Authors: Anthony A Amato; Kumaraswamy Sivakumar; Namita Goyal; William S David; Mohammad Salajegheh; Jens Praestgaard; Estelle Lach-Trifilieff; Anne-Ulrike Trendelenburg; Didier Laurent; David J Glass; Ronenn Roubenoff; Brian S Tseng; Steven A Greenberg Journal: Neurology Date: 2014-11-07 Impact factor: 9.910
Authors: A David Paltiel; Einar Ingvarsson; Donald K K Lee; Richard L Leff; Richard J Nowak; Kurt D Petschke; Seth Richards-Shubik; Ange Zhou; Martin Shubik; Kevin C O'Connor Journal: Muscle Nerve Date: 2015-02-17 Impact factor: 3.217